Movatterモバイル変換


[0]ホーム

URL:


CN100494214C - Small interfering ribonucleic acid sequence of hepatitis B virus gene and its preparation method - Google Patents

Small interfering ribonucleic acid sequence of hepatitis B virus gene and its preparation method
Download PDF

Info

Publication number
CN100494214C
CN100494214CCNB2006101469676ACN200610146967ACN100494214CCN 100494214 CCN100494214 CCN 100494214CCN B2006101469676 ACNB2006101469676 ACN B2006101469676ACN 200610146967 ACN200610146967 ACN 200610146967ACN 100494214 CCN100494214 CCN 100494214C
Authority
CN
China
Prior art keywords
sirna
sequence
hepatitis
gene
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2006101469676A
Other languages
Chinese (zh)
Other versions
CN101077883A (en
Inventor
朱海红
陈智
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang University ZJU
Original Assignee
Zhejiang University ZJU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang University ZJUfiledCriticalZhejiang University ZJU
Priority to CNB2006101469676ApriorityCriticalpatent/CN100494214C/en
Publication of CN101077883ApublicationCriticalpatent/CN101077883A/en
Application grantedgrantedCritical
Publication of CN100494214CpublicationCriticalpatent/CN100494214C/en
Anticipated expirationlegal-statusCritical
Expired - Fee Relatedlegal-statusCriticalCurrent

Links

Landscapes

Abstract

Translated fromChinese

本发明提供乙肝病毒(HBV)基因的小干扰核糖核酸(siRNA)序列及制备方法,SEQ ID NO.1-4为本发明提供的转录siRNA的2对针对HBV(ayw亚型)S基因的DNA模板序列,用体外转录方法合成针对HBV(ayw亚型)基因的特异siRNA,经转染细胞后,达到抑制HBV基因表达的目的。该方法可快速、经济、较大量地获得抗HBV的siRNA,为抗HBV的实验研究和临床应用提供技术和大量siRNA。The present invention provides small interfering ribonucleic acid (siRNA) sequence and preparation method of hepatitis B virus (HBV) gene, and SEQ ID NO.1-4 is the DNA for HBV (ayw subtype) S gene of 2 pairs of transcription siRNA provided by the present invention The template sequence is used to synthesize specific siRNA against HBV (ayw subtype) gene by in vitro transcription method, and the purpose of inhibiting HBV gene expression is achieved after transfecting cells. The method can obtain the anti-HBV siRNA quickly, economically and in large quantities, and provides technology and a large amount of siRNA for the experimental research and clinical application of the anti-HBV.

Description

The Smal linterference ribonucleic acid sequence of hepatitis B virus gene and preparation method
(this case is dividing an application of application number 200410089359.7)
Technical field
The invention belongs to biotechnology, relate to gene engineering technology field, relate in particular to Smal linterference ribonucleic acid sequence and preparation method at hepatitis B virus gene.
Background technology
(1) the treatment present situation of hepatitis B virus (HBV)
Chronic hepatitis B is one of disease occurred frequently of China, is the major cause that causes hepatic fibrosis and liver cancer.If at present the drug main of treatment hepatitis B is based on the immunomodulator of interferon-alpha with based on the nucleoside analog of lamivudine, Adefovir, but result of treatment still is unsatisfied with.HBV DNA to continue to duplicate be the major cause that causes the hepatitis B chronicity.Therefore effectively suppressing the HBV dna replication dna, is the key of treatment chronic hepatitis B and control HBV persistent infection.
(2) RNA interferential present situation
Recently, (RNA interference, the RNAi) appearance of technology have injected new vitality for the treatment of resistant to viral disease in the RNA interference.In decades, RNA is regarded as merely from DNA and obtains genetic information, and information is passed to protein.But discover that recently small fragment RNA (small RNA) is being brought into play the effect of gene regulating, it can close expression of gene, or changes the level [1] of genetic expression.It is verified in mammalian cell that reality is tested research, the double-stranded RNA of 21-23 length of nucleotides (double-stranded RNA, dsRNA), specific RNA can effectively degrade, thereby the expression of blocking protein [2,3], the dsRNA of these length-specifics is called as siRNA (small interfering RNAs).Further mechanism is discovered, siRNA not only can be in the function of post-transcriptional level silence (transcriptionalgene silencing PTGS) specific gene, can also be in DNA and transcriptional level regulatory gene (transcriptional gene silencing, expression TGS) [4].Research now mainly concentrates on post-transcriptional level, after forming, siRNAs at first enters RISC complex body (RNA induced silencingcomplex) in cytoplasm, under the effect of ATP and helicase etc., untwist into strand, antisense strand is attached on the RNA of particular sequence by the base complementrity mode, the specific RNA sequence of cutting under the assistance of RISC complex body, thus degradation of rna makes it to translate into protein, cause this specific gene silence (gene silencing), lose function [4].Simultaneously, RNAi has high degree of specificity, the almost expression of suppressor gene fully of the double-stranded RNA of 19 pairs of Nucleotide (its 3 ' end plug-in 2 uracil sequences [5]), and after one of them coding mutation fallen, it has just disappeared to the restraining effect of gene, this application to siRNA is very important, can avoid siRNA degraded and said target mrna other the mRNA[5 with family].In addition, existing discovering, RNAi is except expressing in the post-transcriptional level regulatory gene, and can make the homologous DNA sequence structure that methylates, thereby has important regulation at transcriptional level, the dsRNA of confirmations such as Mette and NOSPro gene promoter area homologous 23nt can directly cause the methylating of dna sequence dna of goal gene, causes transcribing inactivation [6].
RNAi is as cell " immunity " system on a kind of RNA basis, be applied to anti-virus infection recently and the research of duplicating in, and in the experiment in vitro of HIV, obtained comparatively ideal result, action intensity is considerably beyond antisense nucleic acid and ribozyme technology [7].Rossi etc. with HIV-1 encode rev gene and with its homologous double-stranded RNA cotransfection in 293 cells, the rev expression of gene is significantly suppressed; With retarding effect and the sense-rna of siRNA, ribozyme etc. compare simultaneously, find to have only the siRNA group to suppress the expression of HIVrev-EGFP, its inhibiting rate reaches 90%, and sense-rna, ribozyme group and control group do not have significant difference [7], and this result is confirmed [8] by scholars such as Sharp equally.In RNAi research, there are some researches show: can effectively suppress the expression [10] of duplicating of HCV RNA and viral protein at the siRNA of HCV gene target sequence at virogene of hepatitis.Because what RNA disturb to adopt is double-stranded RNA, it is more stable, be difficult for being degraded, so RNA disturbs not only external, and also has effect preferably in animal body.Therefore, the discovery of RNAi phenomenon is chosen as one of 2002 ten big science achievements by " SCIENCE " magazine and AAAS, has broad application prospects.Consistently now think that the siRNA at virogene is best therapeutic strategy [9].
(3) 5 kinds of methods of RNA interferential
At present, be used for RNA interferential method and mainly contain 5 kinds: (1) chemical synthesis: directly by the synthetic dsRNA of chemical process, its advantage be fast, resultant quantity is bigger, but cost an arm and a leg; (2) in-vitro transcription method: with Oligo DNA is template, and by the synthetic siRNAs of in-vitro transcription, the relative chemosynthesis of cost is lower, and can obtain siRNAs sooner than chemical synthesis.What deserves to be mentioned is that the siRNAs toxicity that in-vitro transcription obtains is little, good stability, the efficient height, 1/10 of the general siRNA amount that only needs chemosynthesis just can reach equal effect.But technical difficulty is bigger; (3) RNaseIII degrading dsRNA method: after the method preparation of said target mrna with 200~1000 bases with in-vitro transcription, use RNaseIII in external digestion then, obtain the mixture of multiple siRNA, its advantage is to study the phenotype of certain gene function disappearance fast and economically, but be not suitable for long research project, or need a specific siRNA to study particularly gene therapy; (4) siRNA expression vector method: the carrier of construction expression specific siRNA, import and express siRNA in the eukaryotic cell, have the advantage that can increase in a large number, but have the potentially dangerous of gene integration; (5) siRNA expresses framework (siRNA expressioncassettes) method: the dna profiling that directly obtains expressing siRNA by PCR method, be transcribed into siRNA in vivo after importing eukaryotic cell, its advantage is that method is simple, speed is fast, can be used for screening effective siRNA sequence, but also have the potentially dangerous of gene integration.
The relative merits and the RNA that make a general survey of above-mentioned 5 kinds of methods disturb the experimental study of chronic HBV infection and the prospect in the clinical application of being applied in, and the present invention selects the dsRNA of the synthetic particular target sequence of in-vitro transcription method.
Summary of the invention
The invention provides small interference ribonucleic acid (siRNA) sequence and the preparation method of hepatitis B virus (HBV) gene, SEQ ID NO.1-4 is a dna profiling sequence of transcribing 2 couple of siRNA at HBV (ayw hypotype) S gene provided by the invention, with the synthetic special siRNA of in-vitro transcription method at HBV (ayw hypotype) gene, behind transfectional cell, reach the purpose that suppresses HBV genetic expression.This method can be fast, economic, relatively large the siRNA that obtain anti-HBV, for experimental study and the clinical application of anti-HBV provides technology and a large amount of siRNA.
The invention provides 2 couple of transcribing siRNA dna profiling sequence at HBV (ayw hypotype) S gene:
SEQ?ID?NO.1(Antisense?anti-s?siRNA1?Oligonucleotide?template)
5’-AAACCTTCGGACGGAAATTGCCCTGTCTC-3’
SEQ?ID?NO.2(Sense?anti-s?siRNA1?Oligonucleotide?template)
5’-AAGCAATTTCCGTCCGAAGGTCCTGTCTC-3’
SEQ?ID?NO.3(Antisense?anti-s?siRNA2?Oligonucleotide?template)
5’-AATACCGCAGAGTCTAGACTCCCTGTCTC-3’
SEQ?ID?NO.4(Sense?anti-s?siRNA2?Oligonucleotide?template)
5’-AAGAGTCTAGACTCTGCGGTACCTGTCTC-3’
2 pairs of dna profiling sequences at HBV (ayw hypotype) S gene of the present invention realize by following steps:
(1) design of siRNA
(2) design of transcribing template of specific siRNA and synthetic
(3) annealing
(4) benefit is flat
(5) transcribe
(6) template degraded
(7) cross column purification
Embodiment
The present invention is described further in conjunction with the embodiments.
Embodiment one external expression of transcribing synthetic RNA interfering vitro inhibition HBV surface antigen blending gene
The preparation of siRNA
(1) experimental result of siRNA is directly synthesized in the principle of design of the design consideration siRNA of siRNA and utilization, chooses the target cDNA target sequence at 2 siRNA of HBV (ayw hypotype) S gene.Sequence is as follows:
(anti-s?siRNA1)5’-AAACCTTCGGACGGAAATTGC-3’
(anti-s?siRNA2)5’-AATACCGCAGAGTCTAGACTC-3’
(2) design of transcribing template of specific siRNA and synthetic according to above-mentioned cDNA target sequence, the DNA that designs and synthesizes two sections 29-mer is as template, comprise that 8 start in the base (being called homing sequence, leader sequence) of primer 3 ' end coupling and the siRNA sequence of 21 designs with T7.
1. the antisense strand of specificity anti-s siRNA1 and positive-sense strand are as follows:
Antisense?anti-s?siRNA1?Oligonucleotide?template
5’-AAACCTTCGGACGGAAATTGCCCTGTCTC-3’
Sense?anti-s?siRNA1?Oligonucleotide?template
5’-AAGCAATTTCCGTCCGAAGGTCCTGTCTC-3’
2. the antisense strand of specificity anti-s siRNA2 and positive-sense strand are as follows:
Antisense?anti-s?siRNA2?Oligonucleotide?template
5’-AATACCGCAGAGTCTAGACTCCCTGTCTC-3’
Sense?anti-s?siRNA2?Oligonucleotide?template
5’-AAGAGTCTAGACTCTGCGGTACCTGTCTC-3’
(3) annealing mixes these two templates and corresponding T7 promoter primer respectively, the terminal and dna profiling annealed combination of primer.
2μl?T7?promoter?primer
6μl?DNA?Hyb?buffer
The template of 2 μ l justice or antisense
70℃,5min→room?temp,5min
(4) mend flat putting down and become the double-stranded DNA template with the big segment benefit of archaeal dna polymerase Klenow.
In above-mentioned reaction tubes, add:
2μl?10×Klenow?Reaction?buffer
2μl?10×dNTP?Mix
4μl?Nucl?ease-free?water
2μl?Exo-klenow
Soft mixing, 37 ℃, 30min;
(5) transcribe respectively and carry out in-vitro transcription with t7 rna polymerase, product is mixed forming dsRNA, new double-stranded RNA comprises homing sequence and 19 base sequences of middle complementary and 3 ' end two multiple U (UU) of 5 ' end strand.
Add in each responsive transcription pipe:
2 μ l justice or antisense siRNA template
4μl?Nuclease-free?water
10μl?2×NTP?Mix
2μl?10×T7?Reaction?buffer
2μl?T7?Enzyme?Mix
Soft mixing, 37 ℃, 2hr;
Justice and antisense transcription product mix, and place 37 ℃ to spend the night
(6) the template degraded is by DNA enzyme liberating template, use simultaneously the single-minded nuclease digestion of strand 5 ' homing sequence, because RNase can not cut the U base and can not cut double-stranded RNA, double-stranded siRNAs of the 21-mer that so the product that obtains is exactly for we to be needed---19 base complementrities are arranged, and 3 ' end respectively has 2 U outstanding.
Add in the above-mentioned reactant:
6μl?Digestion?buffer
48.5μl?Nuclease-free?water
3μl?RNase
2.5μl?DNase
Behind the mixing, 37 ℃, 2hr;
(7) cross the purifying pillar that column purification provides by test kit, remove impurity such as primer, base salt and protein, the siRNAs that can transform usefulness exactly immediately that obtains, by specification carries out.
Embodiment 2 anti-s siRNA suppress the green fluorescent protein expression of reporter plasmid pGFP-S and siRNA cotransfection HepG2 cell and the experiment of HBV S genetic expression
(1) reporter plasmid pGFP-S and siRNA cotransfection HepG2 cell reporter plasmid pGFP-S are the plasmids of expressing reporter gene green fluorescent protein and HBsAg fusion rotein.The HepG2 cell is according to 1 * 10524 orifice plates are inoculated in/hole, cultivate to reach the 80%-90% fusion rate after 24 hours, and cotransfection pGFP-S and siRNA, concrete steps are with reference to the Lipofectamine2000 of Invitrogen company specification sheets.Change 10%FCS DMEM after 6 hours, the feminine gender group of a transfection pGFP-S carrier is set simultaneously, every group is repeated 3 holes.
(2) fluorescence microscope cell green fluorescent protein was expressed transfection after 48 hours, and (DMIRB Leica) observes the expression of green fluorescent protein in the HepG2 cell down at inverted fluorescence microscope.The result shows that compare with the feminine gender group of pGFP-S carrier, the fluorescence intensity of the HepG2 cell of transfection pGFP-S and anti-S siRNA weakens, and the fluorocyte number reduces.
(3) flow cytometer observation of cell green fluorescent protein was expressed transfection after 48 hours, conventional digestion HepG2 cell, and centrifugal suspension is resuspended in PBS, and flow cytometer detects the positive cell number ratio and the average fluorescent strength of express fluorescent protein.The result shows, compares with the feminine gender group of pGFP-S carrier, and the positive cell number ratio of the HepG2 of transfection pGFP-S and siRNA reduces, and average fluorescent strength reduces.
(4) reverse transcription-real-time fluorescence quantitative PCR method detects the expressed rna preparation of HBV S gene RNA: transfection was gathered in the crops the HepG2 cell after 72 hours, Trizol method extracting RNA, and method is with reference to Invitrogen company specification sheets.Reverse transcription, process is with reference to the MBI process specifications.Fluorescence dye standard measure PCR, upstream primer: 5 '-CTCACAATACCGCAGAGTC-3 '; Downstream primer: 5 '-TAAACTGAGCCAGGAGAAA-3 '; Internal reference GAPDH, upstream primer: 5 '-ACAGTCAGCCGCATCTTCTTT-3 ', downstream primer: 5 '-GCAACAATATCCACTTTACCAGAG-3 ' .PCR condition is: 95 ℃ of 3min, 94 ℃ of 30s again, 56 ℃ of 30s, 72 ℃ of 45s, 25 circulations, 72 ℃ of fluoroscopic examination point selection.Do positive control (being template group directly) and negative control (not adding template group) simultaneously with the pGFP-S plasmid DNA.Real-time quantitative PCR detects in 25 circulation fixed points and shows that compare with negative control, anti-S siRNA1 and anti-SsiRNA2 all reach more than 50% the inhibiting rate of S gene.
Embodiment 3anti-s siRNA suppresses the experiment to the HBsAg of siRNA transfection HepG2.2.15 cell and HbeAg expression
(1) siRNA transfection HepG2.2.15 cell HepG2.2.15 cell is according to 1 * 104Inoculate 24 orifice plates, cultivate and reach the 30%-40% fusion rate after 24 hours, each 0.84 μ g of transfection siRNA, concrete steps are referring to the OLIGOFECTAMINE of Invitrogen company reagent specification sheets.Irrelevant contrast siGFP group (FEBS Letters 543 (2003) 51-54) is set: sense RNA 5-GGCUACGUCCAGGAGCGCACC-3, anti-sense RNA 5-UGCGCUCCUGGACGUAGCCTT-3.Change 10%FCS DMEM after 6 hours.Establish 3 multiple holes for every group.
(2) 48h behind radioimmunology detection HBsAg and the HBeAg change in concentration transfection HepG2.2.15 cell, difference collecting cell nutrient solution, centrifugal removal cell debris, supernatant carry out radioimmunology and detect, and detection method illustrates referring to test kit.Behind transfection anti-S siRNA1 and the anti-S siRNA2, HBsAg in the HepG2.2.15 cell conditioned medium and the concentration of HBeAg are low than the HepG2.2.15 cell, and anti-SsiRNA1 and anti-S siRNA2 all reach more than 60% the inhibiting rate of HBsAg and HBeAg.

Claims (3)

Translated fromChinese
1.乙肝病毒基因的小干扰核糖核酸序列,其特征是:该小干扰核糖核酸序列的体外转录的反义DNA模板序列和正义DNA模板序列分别为SEQ IDNO.1和SEQ ID NO.2:1. The small interfering ribonucleic acid sequence of hepatitis B virus gene is characterized in that: the antisense DNA template sequence and the sense DNA template sequence of the in vitro transcription of this small interfering ribonucleic acid sequence are respectively SEQ ID NO.1 and SEQ ID NO.2:SEQ ID NO.1  5’-AATACCGCAGAGTCTAGACTCCCTGTCTC-3’SEQ ID NO.1 5'-AATACCGCAGAGTCTAGACTCCCTGTCTC-3'SEQ ID NO.2  5’-AAGAGTCTAGACTCTGCGGTACCTGTCTC-3’。SEQ ID NO.2 5'-AAGAGTCTAGACTCTGCGGTACCTGTCTC-3'.2.根据权利要求1所述的乙肝病毒基因的小干扰核糖核酸序列的制备方法,通过以下步骤实现:2. the preparation method of the small interfering ribonucleic acid sequence of hepatitis B virus gene according to claim 1, realize by the following steps:(1)选取针对HBVS基因的siRNA的靶DNA序列:5’-AATACCGCAGAGTCTAGACTC-3’;(1) Select the target DNA sequence of the siRNA against the HBVS gene: 5'-AATACCGCAGAGTCTAGACTC-3';(2)设计并合成两段29-mer的DNA作为模板,包括8个与T7启动子引物3′端匹配的碱基和21个设计的siRNA序列,分别为SEQ ID NO.1和SEQ IDNO.2;(2) Design and synthesize two 29-mer DNAs as templates, including 8 bases matching the 3′ end of the T7 promoter primer and 21 designed siRNA sequences, which are SEQ ID NO.1 and SEQ ID NO. 2;(3)将这两个模板和对应的T7启动子引物分别混合,引物末端和DNA模板退火结合;(3) The two templates are mixed with the corresponding T7 promoter primers respectively, and the ends of the primers are annealed to the DNA template;(4)用DNA聚合酶Klenow大片断补平成为双链DNA模板;(4) Use DNA polymerase Klenow large fragments to fill up and become a double-stranded DNA template;(5)分别用T7RNA聚合酶进行体外转录,将产物混合形成dsRNA,新的双链RNA包含5′端单链的引导序列和中间互补的19个碱基序列以及3′端两个重复的U(UU);(5) Use T7 RNA polymerase to perform in vitro transcription, and mix the products to form dsRNA. The new double-stranded RNA contains a single-stranded guide sequence at the 5′ end, a complementary 19-base sequence in the middle, and two repeated U at the 3′ end. (UU);(6)通过DNA酶降解模板,同时用单链专一的核酸酶消化5′的引导序列,由于RNase不能切开U碱基也不能切双链RNA,所以得到的产物就是我们需要的21-mer的双链siRNAs——有19个碱基互补,3′端各有2个U突出;(6) The template is degraded by DNase, and the 5' guide sequence is digested with a single-stranded specific nuclease. Since RNase cannot cut U bases or double-stranded RNA, the product obtained is the 21- mer double-stranded siRNAs - 19 complementary bases with 2 U overhangs at each 3′ end;(7)通过试剂盒提供的纯化小柱,去除引物、碱基盐和蛋白质杂质,得到siRNA。(7) Remove primers, base salts and protein impurities through the purification column provided by the kit to obtain siRNA.3.根据权利要求1所述的乙肝病毒基因的小干扰核糖核酸序列在制备抑制乙肝病毒基因表达药物中的应用。3. the application of the small interfering ribonucleic acid sequence of the hepatitis B virus gene according to claim 1 in the preparation of medicines for inhibiting hepatitis B virus gene expression.
CNB2006101469676A2004-12-072004-12-07 Small interfering ribonucleic acid sequence of hepatitis B virus gene and its preparation methodExpired - Fee RelatedCN100494214C (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
CNB2006101469676ACN100494214C (en)2004-12-072004-12-07 Small interfering ribonucleic acid sequence of hepatitis B virus gene and its preparation method

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
CNB2006101469676ACN100494214C (en)2004-12-072004-12-07 Small interfering ribonucleic acid sequence of hepatitis B virus gene and its preparation method

Related Parent Applications (1)

Application NumberTitlePriority DateFiling Date
CNB2004100893597ADivisionCN1312283C (en)2004-12-072004-12-07 Small interfering ribonucleic acid sequence of hepatitis B virus gene and its preparation method

Publications (2)

Publication NumberPublication Date
CN101077883A CN101077883A (en)2007-11-28
CN100494214Ctrue CN100494214C (en)2009-06-03

Family

ID=38905569

Family Applications (1)

Application NumberTitlePriority DateFiling Date
CNB2006101469676AExpired - Fee RelatedCN100494214C (en)2004-12-072004-12-07 Small interfering ribonucleic acid sequence of hepatitis B virus gene and its preparation method

Country Status (1)

CountryLink
CN (1)CN100494214C (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN101948834B (en)*2010-09-162012-07-04山东大学siRNA for treating HBV
CN101979557B (en)*2010-10-282015-07-01百奥迈科生物技术有限公司SiRNA molecule and application thereof to antiviral medicaments
CN101979555B (en)*2010-10-282015-01-21百奥迈科生物技术有限公司Small interference RNA molecule and application thereof
CN102154267B (en)*2010-12-282013-02-27浙江大学 Single-stranded non-coding MicroRNA four and its application
CN102517255B (en)*2011-12-162013-06-19武汉大学Stably-copied cell line containing hepatitis B viruses, preparation method and application
CN104059916A (en)*2014-06-172014-09-24湖北医药学院附属太和医院Sequence of hepatitis B virus (HBV) specific microRNA like siRNA (msiRNA) and application thereof
JOP20200092A1 (en)*2014-11-102017-06-16Alnylam Pharmaceuticals IncHEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
KR20210043647A (en)2018-08-132021-04-21알닐람 파마슈티칼스 인코포레이티드 Hepatitis B virus (HBV) dsRNA preparation composition and method of use thereof
CN114621954B (en)*2021-04-132023-01-31厦门甘宝利生物医药有限公司RNA inhibitor for inhibiting hepatitis B virus gene expression and application thereof

Also Published As

Publication numberPublication date
CN101077883A (en)2007-11-28

Similar Documents

PublicationPublication DateTitle
EP1725660B1 (en)Multiple promoter expression cassettes for simultaneous delivery of rnai agents
US9453219B2 (en)Cosmetic designs and products using intronic RNA
EP1784492B1 (en)Multiple rna polymerase iii promoter expression constructs
US20110105593A1 (en)MicroRNA-Formatted Multitarget Interfering RNA Vector Constructs and Methods of Using The Same
CN101755049B (en)Primary micro RNA expression cassette
JPWO2009044899A1 (en) Nucleic acids that control cell growth
JP2005508177A (en) In vitro synthesis method of short double-stranded RNA
ZA200601368B (en)A self-processing RNA expression cassette
CN107683336A (en)Agents for treating Hepatitis B Virus (HBV) infection and uses thereof
CN100494214C (en) Small interfering ribonucleic acid sequence of hepatitis B virus gene and its preparation method
Gao et al.Inhibition of hepatitis B virus gene expression and replication by artificial microRNA
CN1312283C (en) Small interfering ribonucleic acid sequence of hepatitis B virus gene and its preparation method
US20110008885A1 (en)Linear double-stranded rna molecule interfering with different target genes
CN101254171B (en)Spray containing small molecule disturbance ribonucleic acid
CN100357436C (en)SiRNA for inhibiting Stat3 gene expression and preparation thereof
EP3881850B1 (en)Composition for inhibiting replication of hepatitis b virus
CN103205461B (en)SiRNA expression vector and application thereof
CN120366294A (en) sRNA, composition and application thereof
HK1162044A (en)Multiple promoter expression cassettes for simultaneous delivery of rnai agents

Legal Events

DateCodeTitleDescription
C06Publication
PB01Publication
C10Entry into substantive examination
SE01Entry into force of request for substantive examination
C14Grant of patent or utility model
GR01Patent grant
C17Cessation of patent right
CF01Termination of patent right due to non-payment of annual fee

Granted publication date:20090603

Termination date:20100107


[8]ページ先頭

©2009-2025 Movatter.jp